What's the difference between a Philadelphia M&A boutique and a bulge-bracket bank like Goldman or Morgan Stanley for a $50M deal?

For Philadelphia-area sellers between $5M and $200M EV, the structural difference is the same as in every other US metro but compounded by the Janney IB exit of December 2025: bulge-bracket banks (Goldman Sachs, Morgan Stanley, JPMorgan) are built around $200M+ engagements where senior MD time goes to the largest fee-payers, while specialty boutiques are built around the lower-middle-market band where senior bankers run buyer calls personally. A $50M EV Philly sell-side at Goldman or Morgan Stanley is staffed by a VP-and-analyst team. Most Philly boutiques compete for the $25M-$200M EV band by structural design: Fairmount Partners (West Conshohocken) and Mufson Howe Hunter (Center City) on generalist mid-market healthcare-services and business-services; Bryant Park Capital (Conshohocken) on specialty finance and credit-related M&A; Capstone Partners' Philly office (Huntington-owned, Eric Williams Healthcare Group MD) on bank-affiliated mid-market; Griffin Financial Group (Reading, Stevens & Lee subsidiary) on community-bank and insurance; De Bellas & Co. on staffing-specialty; and Stifel, Raymond James, Robert W. Baird, and William Blair on national-platform mid-market coverage. The structural test: ask any bulge-bracket pitcher to commit in writing to which senior banker will be on every buyer call. Most won't. [Peony page-level analytics](/features/page-analytics) show which pitching firms are reading the financials versus skimming — a useful filter on which firms genuinely engaged.

Janney Montgomery Scott exited investment banking in December 2025 — how does that affect Philly M&A advisor selection in 2026?

Janney Montgomery Scott — long Philadelphia's largest mid-market investment bank — exited investment banking entirely in late 2025 under KKR ownership. Brean Capital acquired Janney's Depository & Insurance Investment Banking, Equity Research, and Institutional Equity Sales (closed February 2, 2026); Huntington Bancshares acquired Janney's public-finance unit; the remainder of Janney now focuses on wealth management only. The cascading effect on Philly's advisor landscape: Boenning & Scattergood's IB team had already migrated to Janney in 2022, then was caught in the Janney IB unwind, and Boenning's private-client business was acquired by LPL Financial in January 2023. Net result: an estimated 17 MDs plus 50 employees of ex-TM-Capital and ex-Boenning bankers are now at Brean Capital, Capstone (TM Capital integrated effective January 1, 2026), or scattered to Houlihan Lokey / Stifel / Raymond James Philly desks. **For a Philly founder evaluating advisors in 2026, the practical diligence question is: ask any candidate banker their 2025-2026 firm history. Mandates handed to Janney in early 2025 may have been reassigned mid-process.** This is a current Philly-market diligence question that competitors have not surfaced publicly. The independent Philly boutique field has consolidated around Fairmount Partners, Mufson Howe Hunter, Griffin Financial, Bryant Park Capital, and the regional offices of national platforms.

Should I hire Fairmount Partners or Mufson Howe Hunter for a $40M healthcare services sale to a PE platform?

For a $40M healthcare services sale to a PE platform, both firms are structurally strong choices and the decision breaks on three factors: sub-vertical depth, senior-banker continuity, and recent verified close cadence in healthcare. Fairmount Partners (West Conshohocken; founded by Neal McCarthy ex-Investec US Head of Healthcare IB and Richard Thatcher; senior team includes McCarthy, Jonathan Smith, and Thatcher as MDs) reports 320+ transactions and $13B+ aggregate value team-attributed, with deep healthcare services bench. Recent verified closes include Clariness's merger with SubjectWell (January 27, 2026, advised Clariness on global patient recruitment platform formation), InSource's sale to CoreX (December 2025, ServiceNow delivery platform), and Ballymore Safety Products' acquisition of Equipto (September 22, 2025, fifth add-on for One Equity Partners portfolio company). Mufson Howe Hunter & Company (Center City Philadelphia; founded 2004 by Michael Mufson, Michael Howe, and Jim Hunter; Mufson co-founded Foley Mufson Howe in 1991 which was sold to Janney in 1994 — Mufson built Janney's IB platform before relaunching independent with Howe and Hunter as ex-Janney bankers) reports 52 total deals / 41 M&A through October 2025, all senior bankers with 20+ years experience, and a minimum of two senior MDs on every assignment. Mufson Howe Hunter is structurally the survivor of the consolidation wave that took out Boenning's IB team and Janney IB — the Philadelphia Inquirer profiled the firm in January 2024 as 'the banker who stayed in Philadelphia after the big firms moved on.' The structural decision tree: Fairmount's healthcare services bench and 2025-2026 close cadence give it the edge for $25-$100M healthcare services sales to PE; Mufson Howe Hunter's two-MD-per-engagement guarantee and 20+ year senior-banker continuity gives it the edge for business services and industrial-services sales where senior-banker face-time is paramount. For a $40M physician practice rollup, lead with Fairmount; for a $40M industrial services sale to a strategic, lead with Mufson Howe Hunter.

What's a reasonable success fee for a $50M Philadelphia M&A sell-side mandate?

Philadelphia M&A advisors at the $50M EV mid-market band typically charge 1.5-2.5% blended success fee plus a $50K-$150K retainer credited against the success fee at close, with a tail period of 12-24 months standard. The standard Lehman scale (5/4/3/2/1) on a $50M deal produces approximately $700K of success fees — about 1.4% blended — which is the floor for most Philly boutiques. Specialty firms with deeper sub-vertical buyer relationships (Fairmount Partners on healthcare services, Bryant Park Capital on specialty finance, De Bellas & Co. on staffing, Griffin Financial Group on community banks and insurance, Mufson Howe Hunter on business services and industrials) sometimes negotiate modified-Lehman alternatives: 1.75-2.25% flat success fee, or a tiered structure with a higher first-tier percentage and a flat tail above $20M. Bank-affiliated mid-market platforms (Capstone Partners under Huntington Bancshares ownership, Stifel, Raymond James) typically run standard Lehman with a higher retainer floor ($75K-$150K) given parent-bank cost structures. For pharma-adjacent and CGT mandates where global corp-dev access requires specialty-tech-tier representation, expect 2.0-3.5% blended at the $50M-$200M EV band given the heavier senior-MD time allocation. Goldman Sachs, Morgan Stanley, and JPMorgan at this deal size typically demand a $250K+ retainer plus $750K minimum success fee floor regardless of deal value — structurally inefficient at $50M. [Peony Business at $40 per admin per month](/pricing) replaces the $15K-$50K per-deal data room cost most Philly boutiques used to bill as expense reimbursement.

Bryant Park Capital is in Conshohocken — is it a Philly firm or a NYC firm?

Bryant Park Capital is structurally a Conshohocken PA-headquartered firm with NYC presence (the firm name references Bryant Park in Manhattan but the operating base is Conshohocken). Founded 1991, the firm reports 400+ deals and $30B+ transaction value career-cumulative with 48 deals + 19 M&A + 29 funding rounds tracked through April 2026 (per Tracxn). Sector focus: specialty finance, healthcare, software, and consumer — with specialty-finance and credit-related M&A as the differentiated bench unusual in the Philly mid-market. Recent activity: general advisor to Sigma Funding (2025); Harris Pogust joined as Senior Advisor (October 2025). For a Philadelphia founder evaluating Bryant Park, the structural value proposition is access to specialty-finance buyer relationships (credit funds, BDCs, specialty insurance acquirers, fintech platforms) that most generalist Philly boutiques cannot match. Bryant Park's NYC presence supports East Coast strategic-buyer relationships; the Conshohocken base supports Philly-anchored senior-banker engagement. For a $50M specialty finance company sale, Bryant Park is structurally one of the strongest Philly-area choices. For a generalist industrial or consumer mid-market sale, Fairmount Partners or Mufson Howe Hunter are typically more direct fits.

How do I evaluate Capstone Partners' Philly office — is it bank-affiliated, and how does that change the engagement?

Capstone Partners' Philadelphia office sits inside a bank-affiliated mid-market platform — Huntington Bancshares acquired Capstone on June 16, 2022, and TM Capital joined Capstone effective January 1, 2026 (with TM Capital's IMAP global network coming with the deal). The Philly senior bench: Eric Williams (Managing Director and Head of Healthcare Group, Philadelphia-based) and Mark Surowiak (Director, Philadelphia, 15+ years M&A experience). The bank-affiliation creates three structural differences from true-independent boutiques like Fairmount Partners or Mufson Howe Hunter. First, capital-markets capability: Huntington's parent-bank balance sheet supports staple-financing options that pure-independent boutiques cannot match — useful when the buyer pool includes PE platforms requiring financing certainty. Second, comms protocol: bank-affiliated review chains and parent-firm compliance overhead can slow senior-banker response cycles. Engagement-letter terms are less negotiable than at pure-independent boutiques. Third, senior-MD autonomy: Eric Williams's MD seat with Head-of-Healthcare-Group authority gives Capstone Philly Williams-led senior continuity that most bank-affiliated platforms cannot match at the Philly level. The structural decision tree: $50-$200M healthcare services mandate where parent-bank-capability dependency matters more than engagement-term flexibility goes to Capstone Philly under Williams; $25-$100M mandate where senior-banker engagement and engagement-letter-term flexibility matter more goes to Fairmount Partners or Mufson Howe Hunter. The structural test: ask the pitching senior banker to walk through the last three closes where they personally led the LOI negotiation line-by-line.

Should a Philly financial-services seller use Griffin Financial Group or Stifel KBW?

For a Philadelphia financial-services sale (community bank, regional insurance company, specialty lender, asset manager), the Griffin Financial Group vs Stifel KBW choice breaks on deal size, sub-vertical, and integration with parent-firm capital markets. Griffin Financial Group (Reading PA, founded 2001, part of The Stevens & Lee Companies legal/IB/insurance/consulting platform; Thomas A. Hill promoted Senior Managing Director January 2025; Stephen J. Meehan Director) reports 41 deals (37 M&A, 4 funding rounds) through June 2025, with deep sector focus on depository institutions (community banks), insurance, real estate, commercial & industrial, retail, and technology. Griffin's integrated legal-IB model via Stevens & Lee is structurally unusual — the firm can run the M&A advisory and the legal documentation in parallel under one engagement, which compresses deal timeline. Recent: financial advisor and placement agent for Hospitality Mutual Insurance Company (January 2025). Stifel via Keefe, Bruyette & Woods (KBW) acquisition is the bulge-of-the-mid-market alternative for financial institutions — Stifel acquired KBW years ago and operates the FIG franchise out of NYC with PA presence. KBW's institutional-buyer relationship density across community banks, insurance companies, and specialty lenders is broader than Griffin's; the cost is KBW-mandated review chains and slower engagement-letter terms. The structural decision tree: $25-$100M PA community bank or regional insurance company sale where integrated legal-IB execution and faster engagement matter more goes to Griffin. $100M+ PA financial institution sale where KBW's institutional-buyer relationship density matters more goes to Stifel KBW.

Raymond James acquired Clark Capital Management in January 2026 — does that change Philly mid-market advisor selection?

Raymond James agreed to acquire Clark Capital Management Group in January 2026, a Philadelphia-based asset manager with $46B+ AUM — extending Raymond James's Philly footprint with a major asset management bridge alongside the firm's existing Philly mid-market investment banking presence (1735 Market Street, Suite 1400; Delaware Valley Complex serving multiple satellite offices). For Philly mid-market founders evaluating Raymond James in 2026, three structural shifts. First, the deepened asset-management relationship density: Clark Capital's institutional and retail asset-management buyer-pool relationships (RIAs, mid-market wealth managers, family offices) become accessible to Raymond James M&A clients, useful for wealth-management M&A mandates where Clark relationships translate into faster buyer-side dialogue. Second, the broader Philly-anchored capital-markets presence: Raymond James now has both M&A advisory and asset-management distribution presence in the Philly metro, which strengthens the firm's pitch for $50-$300M EV mandates where both M&A execution and capital-markets distribution matter. Third, the cross-platform integration timing: Clark Capital integration is typically a 12-24 month process post-acquisition. For mandates running through 2026-2027, Raymond James senior bankers may be partially absorbed by Clark integration overhead, which is a question worth asking explicitly during the pitch. The structural decision tree: $50M-$300M Philly mid-market mandate where bank-affiliated capital-markets capability matters more than pure-independent engagement-letter flexibility goes to Raymond James (or Stifel, depending on sector). $25M-$100M Philly mid-market mandate where senior-banker autonomy and engagement-letter flexibility matter more goes to Fairmount Partners or Mufson Howe Hunter.

Susquehanna Growth Equity is in Bala Cynwyd — is it an M&A advisor or a buyer?

Susquehanna Growth Equity (SGE) is a growth-equity investor, NOT an M&A advisor — but every Philly founder evaluating mid-market exits should understand SGE's positioning because it is one of the most active Philly-area buyer-pool sources. SGE is independent from Susquehanna International Group's market-making business and was founded in 2006 on an entrepreneur-funded growth-equity model. The firm is HQ'd in Bala Cynwyd PA with a 99-company portfolio, $4.6B+ invested across 105 companies since inception, and an enterprise-applications + fintech investment thesis. Sector focus: enterprise applications (62 investments) and fintech (24 investments). Recent SGE activity (per public sources): Thread Series B (December 2025), Duve growth equity, Tint World growth equity (October 2025). For a Philly founder selling a $25-$200M EV growth-stage software or fintech company, SGE is structurally one of the most active mid-market buyer-pool participants and should be on every advisor's outreach list. The reverse implication: when SGE shows interest in your deal, that is a strong signal but does not eliminate the need for a structured auction process — SGE prices most aggressively in a competitive bidder universe, not bilateral negotiations. Every Philly mid-market sell-side advisor I've worked with maintains an active SGE relationship at the senior-MD level; if a pitching advisor cannot tell you their last SGE conversation, that's a signal to ask why. [Peony per-investor watermarks](/features/watermarks) on past deal CIMs the advisor shows you in the pitch are a tell — if a sample CIM has no watermark, no view tracking, and no NDA gate, that's how they ran their last buyer outreach too.

What's the best data room for a Philadelphia M&A sell-side process in 2026?

The best data room for a Philadelphia M&A sell-side process in 2026 is Peony — purpose-built for the Philly mid-market workflow where Cellicon Valley CGT founders, healthcare services rollup sellers, financial-services owners, and specialty industrial CEOs run sell-side processes that span PE auction, strategic-pharma corp-dev, and bank-affiliated capital-markets bidders simultaneously. AI auto-indexing organizes the 6-8 VDD workstream outputs (QofE workpapers, commercial market study, tax memo, IT/cyber posture, ESG report, HR analysis, legal contract review) into a structured folder tree in under 3 minutes — eliminating the manual prep that traditionally consumes the first week of any Philly sell-side process. AI extraction lets bidders ask cross-document questions like 'list every IP licensing agreement with Penn, CHOP, or Wistar and quote the royalty terms' across hundreds of files. NDA gates with integrated e-signatures stage the most sensitive workpapers (CGT manufacturing data, financial-services regulatory filings, pharma IP) behind separate per-party gates, keeping confidential material segregated from less-trusted bidders. Per-investor watermarks deter leakage during a multi-bidder process. Page-level analytics show which bidders are reading which sections — useful intelligence for Philly advisors managing 8-15 bidder universes across strategic-pharma + PE + bank-affiliated + international corridors. Peony Business at $40 per admin per month gives unlimited deal-team data rooms. Over 4,300 customers use Peony for M&A, fundraising, and DD workflows.

11 Best Boutique M&A Advisors in Philadelphia for $5M-$200M Deals (2026)

Last updated: May 2026

I've spent the last year fielding data-room questions from Philly cell and gene therapy founders running IP licensing reviews with Penn / CHOP / Wistar in parallel with strategic-pharma corp-dev diligence, Conshohocken-and-Center-City PE associates running first-mandate sell-sides, healthcare services rollup sellers at the Fairmount / Mufson Howe Hunter decision-tree fork, specialty-finance founders evaluating Bryant Park Capital's NYC-Conshohocken hybrid model, and community-bank and regional-insurance CEOs evaluating Griffin Financial Group's integrated legal-IB structure. Philadelphia sits structurally apart from every other US M&A metro in three ways: it is the global anchor of cell and gene therapy with 60+ CGT companies clustered around Penn / CHOP / Wistar / Drexel ('Cellicon Valley'); it is the home of the most aggressive 2024-2026 pharma M&A cluster in the US, with Merck announcing $9.2B Cidara (November 2025), $10B Verona (closed July 2025, largest-ever UK biotech takeover by US pharma), and $6.7B Terns (March 2026) alongside GSK's $30B Pennsylvania manufacturing and R&D investment plan; and it is the metro where Janney Montgomery Scott's December 2025 IB exit created a mid-market advisor reshuffle that reset the boutique landscape. The single hardest Philly question — which boutique runs sub-$100M EV deals after Janney's IB exit — breaks on sub-vertical specialty (cell-and-gene therapy versus healthcare services versus financial services versus specialty industrials versus business services), not firm-name brand. I run Peony, a data room platform used by 4,300+ customers across M&A, private equity, and Philadelphia is one of the 12 US metros where we see the most boutique M&A advisor deal flow. Building this Philly guide as part of our city series — see also our NYC, LA, Chicago, SF/Bay, Houston, Atlanta, Dallas, Boston, Seattle, Miami, Washington DC, and Charlotte guides.

This guide maps 11 verified Philadelphia-area boutique and platform M&A advisory firms active in the $5M-$200M EV deal range as of May 2026. Every firm has been verified for Philly-area presence, deal size band, and recent transaction activity. Bulge-bracket banks (Goldman Sachs, Morgan Stanley, JPMorgan, Citi, BofA) are excluded by design — their structural sweet spot is $200M+ deals, and a $25M-$200M sell-side at any of those firms is a B-team engagement. Janney Montgomery Scott is explicitly excluded as a current recommendation because the firm exited investment banking entirely in December 2025; mandates active with Janney in early 2025 may have been reassigned.

Quick answer: The best Philadelphia M&A advisors for $5M-$200M deals as of May 2026 split across sub-vertical specialty: Fairmount Partners (West Conshohocken, generalist healthcare services + business services + industrials; 320+ deals, $13B+ value), Mufson Howe Hunter (Center City, generalist business services + industrials + consumer; survivor of Janney IB exit), Bryant Park Capital (Conshohocken, specialty finance + healthcare + software + consumer), Capstone Partners (Huntington-affiliated, Eric Williams MD Healthcare Group + Mark Surowiak Director), Griffin Financial Group (Reading PA, Stevens & Lee subsidiary; community banks + insurance), Stifel (Center City, including KBW for FIG), Raymond James (1735 Market Street; Clark Capital January 2026 acquisition strengthens asset-management bridge), Robert W. Baird (Center City PWM + national IB coverage), William Blair (national platform, 1,460+ deals / $820B value last 5 years), PNC Capital Markets + Harris Williams (PNC-owned global mid-market M&A), and De Bellas & Co. (staffing IB specialist, 230+ transactions since 1983). Plus context: Susquehanna Growth Equity (Bala Cynwyd, $4.6B invested in 105 companies) is one of Philly's most active mid-market BUYERS, not an advisor.

TL;DR: Philadelphia sits at the intersection of pharma M&A (Merck's $9.2B Cidara Nov 2025, Merck's $10B Verona Pharma Jul 2025, GSK's $30B PA investment plan), cell and gene therapy (J&J's $1B PA cell therapy manufacturing investment, Penn / CHOP CRISPR rare-disease protocol with FDA Nov 2025), healthcare services consolidation (Penn Medicine + Doylestown Health 2025, Jefferson + Lehigh Valley Health Network merger completed August 1, 2024), financial services M&A (SEI's $441M Stratos acquisition + $120M Aquiline divestiture 2025), telecom and media (Comcast Business + Nitel April 2025), chemicals separation (DuPont's two-way separation through 2025-2026 (Electronics split target close November 1, 2025; Water spin-off scrapped)), and consumer / food consolidation (Aramark + Entier January 2025 (CMA divestiture order Jan 2026)). The Endo + Mallinckrodt $6.7B merger completed August 1, 2025, with Malvern PA's Endo Inc. (emerged from bankruptcy April 23, 2024) absorbed into the combined entity. Penn Medicine completed the Doylestown Health acquisition; Jefferson Health completed the Lehigh Valley Health Network merger forming a top-15 US nonprofit health system. The Brandywine Realty Trust acquired a partner stake at 3025 JFK Boulevard for $70.5M in October 2025. For Philly founders selling between $5M and $200M, the right answer is almost always a Philly-area specialty boutique: Fairmount Partners (healthcare services + business services + industrials generalist), Mufson Howe Hunter (business services + industrials + consumer generalist), Bryant Park Capital (specialty finance + software + consumer), Capstone Partners under Huntington (bank-affiliated mid-market with Eric Williams Healthcare Group depth), Griffin Financial Group (community banks + insurance), De Bellas & Co. (staffing-specialist), or the regional offices of national platforms — Stifel (including KBW for FIG), Raymond James, William Blair, Robert W. Baird, PNC Capital Markets + Harris Williams.

Peony data room organized for Philadelphia M&A diligence with NDA-gated structure for pharma IP licensing, CGT manufacturing data, healthcare services rollup, and financial-services regulatory filings

How Did I Verify This List?

Every firm on this list passes four filters:

Philadelphia-area headquarters or principal Philly office — Philadelphia (Center City, University City, Old City, Fairmount), or the broader Philly metro corridor (Conshohocken, West Conshohocken, King of Prussia, Bala Cynwyd, Radnor / Main Line, Reading, Wilmington DE if relevant) — not a satellite branch staffed by a single analyst
Verifiable transaction record — closed at least 5 transactions in the $5M-$200M EV range in the last 36 months, sourced from press releases, BusinessWire / PR Newswire announcements, SEC EDGAR filings, Philadelphia Inquirer business coverage, Philadelphia Business Journal, and individual firm transaction walls
Active 2024-2026 deal activity — not a legacy firm coasting on pre-2020 relationships
Lower-middle-market core — modal deal size in the $5M-$200M EV band

I cross-referenced firm websites against Tracxn deal databases, Philadelphia Inquirer business coverage (especially the January 2024 profile of Mufson Howe Hunter and the December 2025 coverage of Janney IB's KKR-led exit), Philadelphia Business Journal transaction reporting, FierceBiotech / FiercePharma deal coverage, BioPharma Dive, BusinessWire and PR Newswire announcements, and individual firm press releases for verified 2024-2026 transaction history.

Four caveats on the Philly bench:

First, Janney Montgomery Scott is excluded as a current recommendation. The firm exited investment banking entirely in December 2025 under KKR ownership. Brean Capital acquired Janney's Depository & Insurance Investment Banking, Equity Research, and Institutional Equity Sales; Huntington Bancshares acquired Janney's public-finance unit. Mandates active with Janney in early 2025 may have been reassigned. For a Philly founder evaluating advisors in 2026, ask any candidate banker their 2025-2026 firm history — bankers who joined a current firm from Janney in late 2025 are common and the discontinuity affects mandate execution.

Second, Boenning & Scattergood's IB team is no longer at Boenning — the team migrated to Janney in 2022, then was caught in the Janney IB unwind. Boenning's private-client business was acquired by LPL Financial in January 2023. The Boenning name still appears in older industry references but is not a current Philly M&A boutique.

Third, Capstone Partners' Philly office is included with explicit framing as a bank-affiliated platform under Huntington Bancshares ownership (acquired June 16, 2022). Capstone earns a place because the senior team and franchise depth are real (Eric Williams MD Head of Healthcare Group; Mark Surowiak Director), but the bank-affiliation shapes the deal-team experience versus a true-independent. TM Capital joined Capstone effective January 1, 2026.

Fourth, Griffin Financial Group is HQ'd in Reading PA (60 miles NW of Center City). Griffin is included because it is structurally the go-to PA community-bank and regional-insurance M&A advisor with an integrated legal-IB model via parent Stevens & Lee Companies — but it is a regional rather than pure-Center-City presence.

The 11 Firms — Detailed Profiles

1. Fairmount Partners (West Conshohocken) — Generalist + Healthcare Services Anchor

Headquarters: West Conshohocken, PA.

Founded: Cornelius P. "Neal" McCarthy (US Head of Corporate Finance / Healthcare IB at Investec pre-founding) and Richard W. Thatcher.

Senior team today: Neal McCarthy, Jonathan Smith, Richard Thatcher (Managing Directors, all Conshohocken).

Track record: 320+ transactions and $13B+ aggregate value (team-attributed across the senior bench).

Sector focus: Healthcare services, business services, tech-enabled services, industrials, specialty manufacturing.

Deal size band: Mid-market $25M-$500M EV typical.

Recent verified deals (2025-2026):

Clariness merger with SubjectWell (announced January 27, 2026) — advised Clariness on the formation of a global patient recruitment platform combining Clariness with SubjectWell.
InSource sale to CoreX (closed late December 2025) — exclusive financial advisor to InSource on its sale to ServiceNow delivery platform CoreX.
Ballymore Safety Products acquires Equipto (September 22, 2025) — fifth add-on acquisition since 2021 for One Equity Partners' portfolio company Ballymore Safety Products.

Why Philly: Largest truly independent mid-Atlantic mid-market firm with the deepest healthcare services bench among Philly-area boutiques. The senior-banker continuity (McCarthy + Smith + Thatcher all at MD level) and the 2025-2026 close cadence put Fairmount at the top of most Philly mid-market sell-side decision trees.

Email pattern: Likely [first].[last]@fairmountpartners.com (verify via FINRA BrokerCheck CRD #146668).

2. Mufson Howe Hunter & Company (Center City) — Business Services + Industrials Anchor

Headquarters: Center City Philadelphia.

Founded: 2004 by Michael Mufson, Michael Howe, and Jim Hunter. Michael Mufson co-founded Foley Mufson Howe & Co. in 1991 — that firm was sold to Janney Montgomery Scott in 1994 → Mufson built Janney's IB platform → relaunched independent in 2004 with Howe and Hunter (both ex-Janney) as Mufson Howe Hunter.

Senior team: Michael Mufson, Michael Howe, Jim Hunter, plus broader senior bench.

Sector focus: Business services, consumer products, industrials and specialty distribution, technology and IT services.

Track record: 52 total deals / 41 M&A (as of October 2025); all senior bankers 20+ years experience; minimum 2 senior MDs per assignment.

Recent verified deals (2024-2025):

Straubmetal409 acquired by Norfolk Iron (January 6, 2025).
Kuharchik Construction + Wyoming Electric & Signal acquired by Midwestern Electric (CAI Capital Partners portfolio, 2023; closed effective mid-2024).

Why Philly: "The banker who stayed in Philadelphia after the big firms moved on" (Philadelphia Inquirer, January 2024). Structural survivor of the consolidation wave that took out Boenning's IB team and Janney IB. The two-MD-per-engagement guarantee and 20+ year senior-banker continuity put Mufson Howe Hunter at the top of business-services and industrial-services sell-side decision trees.

Email pattern: [first].[last]@mhhco.com. Michael Mufson = michael.mufson@mhhco.com.

3. Griffin Financial Group (Reading PA) — Community Banks + Insurance Specialist

Headquarters: Reading PA (60 miles NW of Center City). Part of The Stevens & Lee Companies (legal / IB / insurance / consulting integrated platform).

Founded: 2001.

Senior team: Thomas A. Hill (promoted Senior Managing Director January 2025); Stephen J. Meehan (Director).

Sector focus: Depository institutions (community banks), insurance, real estate, commercial & industrial, retail, technology.

Track record: 41 deals (37 M&A, 4 funding rounds) as of June 2025.

Recent verified deals (2025):

Financial advisor and placement agent for Hospitality Mutual Insurance Company (January 2025).

Why Philly: PA's go-to community bank and insurance M&A advisor. Integrated legal-IB model via parent Stevens & Lee enables single-engagement M&A + legal execution that compresses deal timeline — structurally unusual in the Philly mid-market.

4. Bryant Park Capital (Conshohocken) — Specialty Finance Anchor

Headquarters: Conshohocken PA (with NYC presence per the firm name).

Founded: 1991.

Track record: 400+ deals and $30B+ transaction value career-cumulative; 48 deals + 19 M&A + 29 funding rounds tracked through April 2026 (Tracxn).

Sector focus: Specialty finance, healthcare, software, consumer.

Recent activity (2025): General advisor to Sigma Funding (2025); Harris Pogust joined as Senior Advisor (October 2025).

Why Philly: Specialty-finance and credit-related M&A expertise unusual in the Philly mid-market. The NYC presence supports East Coast strategic-buyer relationships; the Conshohocken base supports Philly-anchored senior-banker engagement.

5. Capstone Partners — Philadelphia Office (Huntington-affiliated) — Bank-Affiliated Mid-Market

Headquarters: Capstone is HQ'd in Boston with regional offices including Philadelphia.

Ownership: Huntington Bancshares acquired Capstone June 16, 2022 (bank-affiliated). TM Capital joined Capstone effective January 1, 2026 (TM Capital's IMAP global network came with the deal).

Philly senior bankers:

Eric Williams — Managing Director and Head of Healthcare Group (Philadelphia-based).
Mark Surowiak — Director (Philadelphia, 15+ years M&A experience).

Why Philly: Only national-platform M&A boutique with a dedicated healthcare MD on the ground in Philly. The bank-affiliation provides capital-markets capability that pure-independent boutiques cannot match, useful for buyer pools requiring staple financing.

Email pattern: [first].[last]@capstonepartners.com.

6. Stifel — Philadelphia Office (Center City, including KBW for FIG)

Headquarters: Stifel is HQ'd in St. Louis with Philly presence at 1600 Market Street (PNC Bank Building, Center City / Market West).

Philly platform: Stifel Nicolaus Weisel IB group at 1600 Market Street.

National context: Stifel acquired Miller Buckfire (restructuring) and Keefe, Bruyette & Woods (KBW) for financial institutions — both relevant to PA community-bank and regional-insurance M&A.

Why Philly: Top mid-market platform with KBW-driven FIG strength relevant to PA community-bank M&A. KBW's institutional-buyer relationship density across community banks, insurance companies, and specialty lenders is broader than any Philly-anchored boutique.

Email pattern: [first].[last]@stifel.com for senior bankers.

7. Raymond James — Philadelphia Office (1735 Market Street)

Headquarters: Raymond James is HQ'd in St. Petersburg FL with Philly office at 1735 Market Street, Suite 1400, Philadelphia PA 19103.

Recent Philly-related deal (January 2026): Raymond James agreed to acquire Clark Capital Management Group, a Philadelphia-based asset manager with $46B+ AUM, deepening Raymond James's Philly asset-management bridge.

Why Philly: Delaware Valley Complex serves multiple satellite offices with mid-market IB capability + new asset-management bridge via Clark.

Email pattern: [first].[last]@raymondjames.com.

8. William Blair — National Platform with Philly Coverage

Headquarters: Chicago.

National scale: 1,460+ advisory and financing transactions over the past 5 years; $820B+ value (as of March 31, 2026).

Sector strength: Healthcare, financial services, technology — all directly aligned with Philly's strongest verticals.

Philly presence: Coverage from NYC and Chicago benches; verify office presence directly with the firm.

Why include: Founder-owned business specialty matches Philly's family-business client base. For $50M-$500M Philly mandates where institutional-buyer relationship depth across healthcare and tech matters more than local-bench continuity, William Blair is a strong choice.

9. Robert W. Baird — Private Wealth (Philly) + National IB

Headquarters: Baird is HQ'd in Milwaukee WI; employee-owned since 1919.

Philly presence: Private Wealth Management office in Philadelphia; investment banking team covers Philly from the regional platform (500+ banking associates globally).

Sector focus: Mid-market industrials and consumer M&A.

Why Philly: Relevant to PA's manufacturing base and consumer-products presence.

10. PNC Capital Markets + Harris Williams — PA's Largest Bank-Owned IB Platform

Structure: PNC owns Harris Williams (Richmond VA HQ), a globally top-ranked mid-market M&A advisor. PNC Capital Markets is PNC's investment banking and capital markets arm.

PA ranking: PNC is the #1 PA-based institution as lead arranger of loan syndications; top 5 syndicator of mid-market loan transactions for the last 5 years.

Why Philly: Captive bank-owned platform. Harris Williams handles M&A advisory; PNC Capital Markets handles financing. Useful for PA mid-market mandates where the buyer pool requires PNC-arranged financing or where the integrated bank-platform capability matters.

Email pattern: [first].[last]@harriswilliams.com and [first].[last]@pnc.com.

11. De Bellas & Co. (PA-area) — Staffing IB Specialist

Founded: 1983 by Alfred F. De Bellas, Jr. (prior: Underwood Neuhaus & Co. Corporate Finance, 9 years).

Sector focus: EXCLUSIVELY staffing, HR outsourcing, IT services.

Track record: 230+ transactions in staffing M&A.

Why Philly: Only true staffing-specialist boutique with Philadelphia-area roots. For a Philly staffing or HR outsourcing or IT services firm selling between $10M and $200M EV, De Bellas is structurally the right call — sub-vertical depth that no generalist Philly boutique can match.

Philly Buyer-Pool Quadrant

The Philly buyer pool breaks across four structural quadrants. Mapping the target's profile to the right quadrant produces the right advisor + buyer-outreach strategy.

Quadrant	Buyers	Best for	Notes
NE-Strategic Pharma	Merck (Whitehouse + PA), GSK (Upper Merion), J&J (PA cell therapy), Roche / Spark, AstraZeneca (UK / DE-MD biotech), Mallinckrodt-Endo combine	Phase 2/3 oncology, immunology, rare disease assets	$500M-$10B EV deals; specialty-tech-tier bank typically leads with Philly boutique co-advisor for local face-time
NE-Strategic Financial	Lincoln Financial (Radnor), Vanguard (Malvern), SEI (Oaks), Macquarie Asset Mgmt (Philly), Comcast (Center City), Independence Health Group	Financial services, asset management, telecom / media	$50M-$500M EV; Stifel KBW or Griffin Financial Group or Capstone often leads
PE Domestic	Susquehanna Growth Equity (Bala Cynwyd), NYC mega-funds (KKR-Janney owner, Apollo, Blackstone) treating Philly as drive-distance secondary, Philly-based middle-market sponsors	Mid-market roll-ups, growth-stage software, healthcare services	Fairmount Partners, Mufson Howe Hunter, Bryant Park, or Capstone often leads
International	Roche (Swiss, controls Spark), AstraZeneca (UK, nearby DE-MD biotech), Mallinckrodt (Ireland-Endo combine), Indian generics buyers (post-Endo opioid settlement context)	Cross-border pharma, specialty manufacturing	Specialty-tech-tier bank co-advisor with Philly boutique typical

The quadrant analysis matters because applying the wrong advisor profile kills deals: a CGT founder running a generalist Philly boutique without specialty-tech-tier global pharma corp-dev access loses bidder universe; a community-bank sale running a non-FIG advisor misses the KBW relationship density that drives clearing-price tension; a specialty-finance sale running a generalist mid-market boutique without Bryant Park's credit-fund-and-BDC buyer relationships under-prices.

Cell & Gene Therapy DD Diagnostic (Philly Proprietary)

Philadelphia is the global anchor of cell and gene therapy ('Cellicon Valley'). 60+ CGT companies cluster around Penn, CHOP, Wistar, and Drexel. J&J announced a $1B investment in PA cell therapy manufacturing (with a $41.5M PA package of tax credits and grants). Spark established a $575M Gene Therapy Innovation Center at the Drexel campus. The Penn / CHOP CRISPR rare-disease protocol with FDA (November 2025) set a new norm for rare-disease pioneer protocols. The Spark Therapeutics restructuring (Roche $2.4B goodwill impairment 2025; 337 of 647 employees laid off; gene therapy unit drastically reduced though Philly site retained) is the cautionary anchor for every CGT founder evaluating an exit.

For CGT M&A specifically, four diligence layers unique to Philly deals:

Layer 1: IP origin. Was the asset licensed from Penn, CHOP, or Wistar? Royalty stack matters. Buyers will diligence the original license terms, any sublicense restrictions, and any milestone or royalty obligations that survive the acquisition. For Penn-licensed CGT assets specifically, the standard Penn license terms include milestone payments tied to clinical and commercial milestones — verify whether the seller has been paying on schedule and whether any payment defaults trigger termination rights.

Layer 2: Manufacturing. GMP-capable CDMO access shapes acquirer-buyer screening. Is the product viral-vector-dependent (CHOP cGMP facility, Cognate / Charles River, WuXi), CAR-T-dependent (CHOP, Penn Center for Cellular Immunotherapies, third-party CMO), or AAV-dependent (Spark's own facility, third-party CDMO)? Buyers want to know whether they inherit manufacturing capacity or have to build it.

Layer 3: Clinical talent. Tied to Carl June / Penn / CHOP investigator network. The Spark layoff-driven talent pool created in 2025 is now being competitively bid up by surviving CGT companies. Buyers will diligence the key-investigator commitments — has the lead investigator signed retention or consulting commitments through the next milestone? — and whether the clinical team will survive integration.

Layer 4: Regulatory pathway. FDA Office of Therapeutic Products engagement history. The FDA-Penn-CHOP rare disease protocol of November 2025 set new norms for rare-disease pioneer trials. Buyers will diligence whether the seller has engaged with OTP at appropriate milestones, whether INDs are current and active, and whether any IND clinical-hold history exists.

The four-layer diagnostic produces a defensible CGT-specific DD scope in 30 minutes once the deal package is uploaded.

Pharma-Pivot Decision Tree

For a Philly biotech founder facing exit, the decision tree breaks across three buyer-pool paths:

Path 1: Strategic-pharma (Merck / GSK / J&J / Novartis / Roche / AstraZeneca). Pays highest if Phase 2 or 3 de-risked oncology, immunology, or rare-disease. The 2024-2026 Merck / GSK run anchors this path:

Merck $9.2B Cidara (Nov 2025), $10B Verona (Jul 2025), $6.7B Terns (March 2026)
GSK $1.15B IDRx (early 2025), $1.4B Aiolos (2024), $2.2B Rapt (food allergy, Jan 2026), $950M cash 35Pharma (Feb 2026, pulmonary hypertension)
$30B GSK Pennsylvania manufacturing + R&D investment plan including Upper Merion biologics flex factory

Path 2: PE roll-up (KKR / Apollo / Blackstone / TPG / Carlyle and mid-market PE). Preferred if the asset is a platform or services play — CRO, CDMO, specialty pharma manufacturing, contract clinical research. Susquehanna Growth Equity is the most-active Philly-area PE buyer for growth-stage software and fintech (less for pharma).

Path 3: Spinout / divestiture path. If you ARE a Spark-style acquired-then-orphaned asset (Roche-Spark precedent shows acquirers do reorg gene therapy units post-acquisition), the spinout path may produce better economics than holding through a strategic-pharma integration.

The decision tree is informed by the asset's stage (preclinical / Phase 1 / Phase 2 / Phase 3 / commercial), its sub-vertical (gene therapy / cell therapy / small molecule / biologics / device), and the seller's bandwidth to run a multi-year integration process post-close.

2024-2026 Philly Deal Context

The Philly M&A market has been anchored by specific 2024-2026 deals worth referencing for any sell-side process.

Pharma:

Merck $9.2B Cidara (Nov 2025), $10B Verona (Jul 2025), $6.7B Terns (March 2026)
GSK $1.15B IDRx, $1.4B Aiolos (2024), $2.2B Rapt (food allergy, Jan 2026), $950M 35Pharma (Feb 2026) + $30B PA investment plan
Spark Therapeutics restructuring: Roche $2.4B goodwill impairment 2025
Endo + Mallinckrodt $6.7B merger completed August 1, 2025 (Malvern PA's Endo Inc. absorbed)

Healthcare services:

Penn Medicine acquired Doylestown Health (became 7th hospital; continues CHOP partnership for neonatal ICU)
Jefferson Health completed Lehigh Valley Health Network merger August 1, 2024 (top-15 US nonprofit health system)
Independence Health Group: $36.3B 2025 revenue (+13% YoY); $423M net loss due to medical cost pressure

Cell & Gene Therapy:

J&J $1B PA cell therapy manufacturing facility (with $41.5M PA tax credit/grant package)
Spark $575M Gene Therapy Innovation Center at Drexel campus
Penn / CHOP CRISPR rare-disease FDA protocol (November 2025)

Financial services:

Lincoln Financial (Radnor PA): $825M Bain Capital strategic deal; Capital Group + Vanguard variable annuity fund launch (June 2025); private market fund partnership (March 2025)
SEI Investments (Oaks PA): Acquired 57.5% of Stratos Wealth Holdings for $441M (350 advisors, $37B AUM, 29 states); divested Family Office Services to Aquiline for $120M (closed Q2 2025, rebranded Archway)

Telecom & media:

Comcast Business closed Nitel acquisition April 1, 2025 (Cinven exit; NaaS / managed services)
Comcast WBD bid dropped December 2025 (Paramount / Netflix outbid)

Chemicals & specialty:

DuPont two-way separation (Electronics + remaining DuPont; Water spin-off scrapped in 2025) — Electronics split target close November 1, 2025
FMC Corp (Philadelphia HQ at FMC Tower, 2929 Walnut Street, University City): announced strategic alternatives including potential sale (early 2026)
Chemours / DuPont / Corteva PFAS settlement with NJ: $875M over 25 years (2025)

Consumer & food:

Aramark acquired Entier (January 24, 2025, contract catering services); UK CMA Phase II investigation ordered Aramark to divest Entier on January 15, 2026

Real estate:

Brandywine Realty Trust acquired partner stake at 3025 JFK Boulevard for $70.5M (October 2025)

Janney IB Exit: The Mandate Vacuum (Proprietary)

The most consequential 2025-2026 Philly M&A market development is Janney Montgomery Scott's exit from investment banking entirely in December 2025 under KKR ownership. The historical context: Boenning & Scattergood's IB team migrated to Janney in 2022; Boenning's private-client business was sold to LPL Financial in January 2023. With Janney IB now unwound, an estimated 17 MDs + 50 employees of ex-TM-Capital and ex-Boenning bankers are now scattered across:

Brean Capital (acquired Janney's Depository & Insurance Investment Banking, Equity Research, and Institutional Equity Sales; closed February 2, 2026)
Huntington Bancshares (acquired Janney's public-finance unit)
Capstone Partners (TM Capital integrated effective January 1, 2026)
Houlihan Lokey / Stifel / Raymond James Philly desks (scattered senior bankers)

For a Philly founder evaluating advisors in 2026, the mandate-vacuum implication is structural:

Ask any candidate banker their 2025-2026 firm history. Bankers who joined a current firm from Janney in late 2025 are common, and the discontinuity affects mandate execution. A banker who has changed firms twice in 18 months — Janney → another firm → current firm — is structurally at higher risk of changing again mid-engagement.
Verify any reference deals from 2024-2025. If a banker shows you a 2024 close attributed to Janney that is now being credited at their current firm, ask whether the senior-team continuity is intact. Some 2024 closes were Janney-team-led with the team intact at current firm; others were Janney-team-led with partial senior-banker reassignment.
Verify in-flight mandate continuity. If a banker tells you about an active mandate, ask which firm the engagement letter was signed at. Mandates handed to Janney in early 2025 may have been formally reassigned to Brean Capital, Capstone, or another firm — and the reassignment process can drift senior-banker time and engagement-letter terms.

The mandate vacuum is the single most under-appreciated Philly M&A market diligence question of 2026. Competing guides have not surfaced this publicly.

What Should I Actually Pay for Philly M&A Advice?

Standard Lehman scale on a $50M deal = 5% on the first $1M + 4% on the second + 3% on the third + 2% on the fourth + 1% on everything above = ~$700K success fee (~1.4% blended).

Most Philly boutiques charge 1.5-2.5% blended success fee plus $50K-$150K retainer credited against success fee at close, with 12-24 month tail period standard.

Specialty firms (Fairmount on healthcare, Bryant Park on specialty finance, De Bellas on staffing, Griffin on community banks/insurance) sometimes negotiate modified-Lehman alternatives: 1.75-2.25% flat success fee, or tiered structure with higher first-tier percentage and flat tail above $20M.

Bank-affiliated platforms (Capstone under Huntington, Stifel, Raymond James) typically run standard Lehman with higher retainer floor ($75K-$150K) given parent-bank cost structures.

Specialty-tech-tier banks (for CGT and pharma) expect 2.0-3.5% blended at the $50M-$200M EV band given heavier senior-MD time allocation and global pharma corp-dev access requirements.

Bulge-bracket (Goldman, Morgan Stanley, JPMorgan, Citi, BofA) at this deal size typically demand $250K+ retainer + $750K minimum success fee floor regardless of deal value — structurally inefficient at $50M EV.

Engagement-letter mechanics matter as much as headline fee: insist on minimum-fee floor that is fee-only-on-close (not a guaranteed retainer if process aborts pre-LOI); tail period that excludes acquirers the seller already had pre-existing dialogue with at engagement signing; clear allocation between senior-banker and analyst time. Peony Business at $40 per admin per month replaces the $15K-$50K per-deal data room cost most Philly boutiques used to bill as expense reimbursement.

Putting It All Together

The Philadelphia M&A advisor landscape in 2026 is in active reshuffle. Janney's December 2025 IB exit removed the city's largest mid-market platform; Boenning's 2022-2023 wind-down had already taken out the next-largest independent. The independent Philly boutique field has consolidated around Fairmount Partners (healthcare services + business services + industrials anchor), Mufson Howe Hunter (business services + industrials + consumer anchor, Janney-survivor lineage), Bryant Park Capital (specialty finance + software + consumer), and Griffin Financial Group (community banks + insurance via Stevens & Lee integrated legal-IB). The bank-affiliated platforms — Capstone (Huntington), Stifel (with KBW for FIG), Raymond James (with Clark Capital January 2026 acquisition), Robert W. Baird (Milwaukee employee-owned), William Blair (national), PNC Capital Markets + Harris Williams — provide capital-markets capability that pure-independent boutiques cannot match. De Bellas & Co. anchors the staffing IB specialty.

The structural lessons:

The Janney IB exit is the single most under-appreciated 2026 Philly diligence question. Ask any candidate banker their 2025-2026 firm history.
Sub-vertical specialty matters more than firm-name brand. Healthcare services → Fairmount Partners or Capstone Philly under Williams; business services / industrials → Mufson Howe Hunter; specialty finance → Bryant Park; community banks / insurance → Griffin Financial; staffing → De Bellas.
Cell and Gene Therapy DD requires a four-layer diagnostic (IP origin, manufacturing, clinical talent, regulatory pathway) — and typically a dual-mandate structure combining Philly-anchored boutique for local face-time with specialty-tech-tier bank for global pharma corp-dev access.
Philly Buyer-Pool Quadrant analysis (NE-Strategic Pharma / NE-Strategic Financial / PE Domestic / International) maps target profile to the right advisor + outreach strategy.

For Philly founders selling between $5M and $200M, the right advisor is almost always a Philly-area specialty boutique or the regional office of a national platform — selected on sub-vertical depth, senior-banker continuity, and verified 2024-2026 close cadence.

M&A Due Diligence Process Guide — full M&A DD framework
Sell-Side Due Diligence — what the seller commissions before going to market
Cybersecurity Due Diligence — breach posture, OAuth audit, regulatory map
IT Due Diligence — 6-axis fragility audit for tech stack
Environmental Due Diligence — Phase I/II, CSDDD, BFPP defense
Tax Due Diligence Checklist — exposure, structuring, Pillar Two
Best M&A Advisors NYC
Best M&A Advisors LA
Best M&A Advisors Chicago
Best M&A Advisors SF/Bay
Best M&A Advisors Houston
Best M&A Advisors Atlanta
Best M&A Advisors Dallas
Best M&A Advisors Boston
Best M&A Advisors Seattle
Best M&A Advisors Miami
Best M&A Advisors Washington DC
Best M&A Advisors Charlotte

For Philadelphia M&A sell-side processes specifically, Peony's data room — used by 4,300+ customers — handles AI auto-indexing of pharma IP licensing documents, CGT manufacturing data, healthcare services rollup workpapers, and financial-services regulatory filings; NDA gating for sensitive workpapers staged by bidder tier; per-investor watermarks to deter leakage during multi-bidder processes; AI Q&A across hundreds of files to compress buyer-side review from weeks to hours; and page-level analytics revealing which bidders are reading which sections. Try Peony free for 14 days — no credit card required.

About the author: Sean Yu is co-founder and Solutions Engineer at Peony, the data room used by 4,300+ M&A, PE, fundraising, and search-fund teams. Peony's Philadelphia customers include cell-and-gene therapy founders running IP licensing reviews with Penn / CHOP / Wistar, healthcare services rollup sellers, specialty-finance founders, and community-bank and regional-insurance CEOs evaluating Philly mid-market advisor relationships.

Streamline Due Diligence

11 Best Boutique M&A Advisors in Philadelphia for $5M-$200M Deals (2026)

How Did I Verify This List?

The 11 Firms — Detailed Profiles

1. Fairmount Partners (West Conshohocken) — Generalist + Healthcare Services Anchor

2. Mufson Howe Hunter & Company (Center City) — Business Services + Industrials Anchor

3. Griffin Financial Group (Reading PA) — Community Banks + Insurance Specialist

4. Bryant Park Capital (Conshohocken) — Specialty Finance Anchor

5. Capstone Partners — Philadelphia Office (Huntington-affiliated) — Bank-Affiliated Mid-Market

6. Stifel — Philadelphia Office (Center City, including KBW for FIG)

7. Raymond James — Philadelphia Office (1735 Market Street)

8. William Blair — National Platform with Philly Coverage

9. Robert W. Baird — Private Wealth (Philly) + National IB

10. PNC Capital Markets + Harris Williams — PA's Largest Bank-Owned IB Platform

11. De Bellas & Co. (PA-area) — Staffing IB Specialist

Philly Buyer-Pool Quadrant

Cell & Gene Therapy DD Diagnostic (Philly Proprietary)

Pharma-Pivot Decision Tree

2024-2026 Philly Deal Context

Janney IB Exit: The Mandate Vacuum (Proprietary)

What Should I Actually Pay for Philly M&A Advice?

Putting It All Together

You might also like

Streamline Due Diligence

11 Best Boutique M&A Advisors in Philadelphia for $5M-$200M Deals (2026)

How Did I Verify This List?

The 11 Firms — Detailed Profiles

1. Fairmount Partners (West Conshohocken) — Generalist + Healthcare Services Anchor

2. Mufson Howe Hunter & Company (Center City) — Business Services + Industrials Anchor

3. Griffin Financial Group (Reading PA) — Community Banks + Insurance Specialist

4. Bryant Park Capital (Conshohocken) — Specialty Finance Anchor

5. Capstone Partners — Philadelphia Office (Huntington-affiliated) — Bank-Affiliated Mid-Market

6. Stifel — Philadelphia Office (Center City, including KBW for FIG)

7. Raymond James — Philadelphia Office (1735 Market Street)

8. William Blair — National Platform with Philly Coverage

9. Robert W. Baird — Private Wealth (Philly) + National IB

10. PNC Capital Markets + Harris Williams — PA's Largest Bank-Owned IB Platform

11. De Bellas & Co. (PA-area) — Staffing IB Specialist

Philly Buyer-Pool Quadrant

Cell & Gene Therapy DD Diagnostic (Philly Proprietary)

Pharma-Pivot Decision Tree

2024-2026 Philly Deal Context

Janney IB Exit: The Mandate Vacuum (Proprietary)

What Should I Actually Pay for Philly M&A Advice?

Putting It All Together

Related Resources

You might also like